CytRx's Aldoxorubicin Excites Investors In Wall Street Financial District (NASDAQ:CYTR)

CytRx Corporation (NASDAQ:CYTR)

As the wall street financial district remains lethargic, we would advise you to check out CytRx Corporation ticker symbol CYTR. This Company’s (www.cytrx.com) stock has skyrocketed +56.90% Up 1.36 generating over 20.8 million shares in the financial market at $3.75 per share Wednesday December 11, 2013 11:42AM EST. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Stock market analyst expect the global oncology market to top over US$75 billion by 2013. The HOT topic surrounding CytRx Corporation is its potential cancer treatment aldoxorubicin.

Aldoxorubicin (formerly INNO-206) is a tumor-targeted doxorubicin conjugate in which CytRx Corporation holds its exclusive worldwide rights. Mid stage study results of the treatment indicated a median progression-free survival rate of 8.4 months, in comparison of a 4.7 months rate of those who had taken chemotherapy doxorubicin. The study also concluded that the disease had not move forward after 6 months for 67% of aldoxorubicin patients. CytRx Corporations year to date stock price has Upticked +90.38%.

****

Crown Equity Holdings Inc. (OTCMKTS:CRWE)

while stock market analyst speculate on U.S. Federal Reserve, we would advise you check out Crown Equity Holdings Inc. ticker symbol CRWE. This Company’s (http://crownequityholdings.com) stock has surged +4.44% Up 0.0002 generating over 1.03 million shares in the financial market at $0.0047 per share Wednesday December 11, 2013 10:05AM EST. Crown Equity Holdings Inc. provides a vast array of network services in reference to website distribution and development, investor relations, human resources, video streaming (http://crwetube.com/), and advertisement. Not only has this Company previously founded iB2B Global (To view iB2B Global short form business plan visit URL http://crownequityholdings.com/extras/iB2BGlobal_business_plan.pdf), but they have adding CRWE Network (CRWE-PR) Encinitas (http://encinitas.crwe-pr.com).

With online sales touching US$2.29 billion early December through tablet and smart phone use, investors can’t ingnore the resilience of online advertisement. As Crown Equity Holdings Inc. continues to increase it portfolio expect its fundamentals to increase shareholder value. The Company’s stock has experienced +34.29% uptick in the stock market in reference to its 3 month performance.

****

BG Medicine, Inc. (NASDAQ:BGMD)

As the number of people seeking health insurance under the Affordable Care Act more than doubles, we would advise you check out BG Medicine, Inc. ticker symbol BGMD. This Company’s (www.bg-medicine.com) stock has surged +38.89% Up 0.42 generating over 16.4 million shares in the financial market at $1.50 per share Wednesday December 11, 2013 12:30PM EST. The HOT topic surrounding BG Medicine, Inc. is it Galectin-3(R) Test.

The Centers for Medicare and Medicaid Services have issued the final determination of the 2014 Medicare national limitation amount for the BG Medicine’s galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will swap the galectin-3 blood test’s national limitation amount of $17.80 that was to begin in 2013. The Company’s stock has lauched +57.19% in the stock market in reference to its 3 month performance.

Other Notable Stock’s Today:

Astrotech Corp. (NASDAQ:ASTC) $1.89 Up 0.32 or (+20.38%) Real-time: 12:45PM EST

Echo Therapeutics, Inc. (NASDAQ:ECTE) $3.44 Up 0.51 or (+17.41%) Real-time: 12:49PM EST

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/